The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1401
Drugs for Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The CDC is now recommending that everyone in the US born between 1945 and 1965 be tested for hepatitis C virus (HCV) infection.1

RATIONALE FOR TESTING — The CDC estimates that 3.25% of US adults born between 1945 and 1965 have antibodies against hepatitis C, and that many of them have chronic hepatitis C infection (detectable HCV RNA in serum) and do not know it. The CDC believes that early identification of these patients and appropriate medical care can reduce transmission of the disease and improve health outcomes. Chronic hepatitis C is a risk factor for hepatic cirrhosis, end-stage liver disease and hepatocellular cancer. Treatment with effective antiviral drugs can eradicate the infection and decrease the risk and severity of these complications.

TREATMENT — For many years, the standard therapy for chronic hepatitis C was subcutaneously injected ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Hepatitis C
Article code: 1401a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian